Novelty:
This technology is a novel transrectal ultrasound method and probe for prostate biopsy.
Value Proposition:
Prostate cancer is the most frequently diagnosed non-skin malignancy for men in the U.S. Treatment and monitoring methods rely heavily on biopsy. Current transrectal ultrasound-guided (TRUS) prostate biopsy methods have significant shortcomings and high false-negative rates, largely related to targeting inaccuracies. This technology has the potential to solve these errors with a novel probe and probe path. Other advantages include:
Technical Details:
Johns Hopkins researchers have developed a novel probe and method for prostate biopsy that builds upon current transrectal ultrasound-guided biopsy methods. The probe will be guided robotically and will include imaging methods for more accurate guidance. The probe and method improve on current methods by raising the accuracy level, guiding the biopsy needle robotically, and reducing cost. This technology has the potential to reduce suffering from prostate cancer in addition to lowering the burden and associated healthcare costs.
Looking for Partners:
To develop & commercialize the technology as a robotic method for prostate biopsy.
Stage of Development:
Prototype
Data Availability:
Publications/Associated Cases:
Not at this time
